No single measure was identified for use across the range of FND symptoms in adults .
Across r and omised controlled trials ( k=40 ) and observational treatment studies ( k=40 ) , outcome measures most often assessed core FND symptom change .
Other domains measured commonly were additional physical and psychological symptoms , life impact ( ie , quality of life , disability and general functioning ) and health economics/cost-utility ( eg , healthcare re source use and quality -adjusted life years ) .
CONCLUSIONS There are few well-vali date d FND-specific outcome measures .
OBJECTIVES We aim ed to identify existing outcome measures for functional neurological disorder ( FND ) , to inform the development of recommendations and to guide future research on FND outcomes .
Changes in Emotion Processing following Brief Augmented Psychodynamic Interpersonal Therapy for Functional Neurological Symptoms.
BACKGROUND Functional neurological symptoms ( FNS ) are considered non-volitional and often very disabling , but are not explainable by neurological disease or structural abnormalities . Brief Augmented Psychodynamic Interpersonal Therapy ( BAPIT ) was adapted to treat the putative emotion processing deficits thought to be central to FNS aetiology and maintenance . BAPIT for FNS has previously been shown to improve levels of distress and functioning , but it is unknown whether improvements on such measures correlate with changes in emotion processing ‒ which this treatment focuses on . AIM To determine ( a ) whether the recently developed Emotional Processing Scale-25 can be used to demonstrate BAPIT-associated changes in patients with FNS , and ( b ) whether changes in the EPS-25 are associated with changes in previously vali date d outcome measures . METHOD 44 patients with FNS completed question naires including the EPS-25 and measures of clinical symptomology ( health-related quality of life ( SF-36 ) , somatic symptoms ( PHQ-15 ) , psychological distress ( CORE-10 ) and illness underst and ing ( BIPQ ) ) pre- and post-therapy . RESULTS At group level , emotion processing improved following therapy ( p = .049 ) . Some measures of clinical symptomology also improved , namely health-related quality of life ( p = .02 ) and illness underst and ing ( p = .01 ) . Improvements in the EPS-25 correlated with improvements in mental health-related quality of life and psychological distress . CONCLUSIONS Emotion processing and some measures of clinical symptomology improved in patients with FNS following BAPIT . The EPS-25 demonstrated changes that correlated with previously vali date d outcome measures . The EPS-25 is a suitable measure of psychotherapy-associated change in the FNS patient population
No single measure was identified for use across the range of FND symptoms in adults .
Across r and omised controlled trials ( k=40 ) and observational treatment studies ( k=40 ) , outcome measures most often assessed core FND symptom change .
Other domains measured commonly were additional physical and psychological symptoms , life impact ( ie , quality of life , disability and general functioning ) and health economics/cost-utility ( eg , healthcare re source use and quality -adjusted life years ) .
CONCLUSIONS There are few well-vali date d FND-specific outcome measures .
OBJECTIVES We aim ed to identify existing outcome measures for functional neurological disorder ( FND ) , to inform the development of recommendations and to guide future research on FND outcomes .